theMednet - For a patient with metastatic NSCLC who had progression x2 at a single site treated w RT, would you switch systemic treatment?

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University • NCI-CCC Thoracic Tumor Board Question

For a patient with metastatic NSCLC who had progression x2 at a single site treated w RT, would you switch systemic treatment?

Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation.

Answer from: Medical Oncologist at Community Practice

Continue immunotherapy.

Sign in or Register to read more